• UCLA Health
  • myUCLAhealth
  • School of Medicine
CARE Center

CARE Center  |  AIDS Institute

CARE Center
  • About Us
    • About Us
    • News & Events
    • Our Team
    • Donate
  • Patient Care
    • Medical Care Coordination
  • Clinical Trials
    • FAQs
  • Community
    • Events
    • Community Advisory Board
    • Partner of the Month
    • Prevention CAB
  • Clinical Research Services
    • For Volunteers
    • For Investigators
  • Contact Us
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

CARE Center  |  AIDS Institute

Clinical Trials - Old

Clinical Trials - Old

Clinical Trials - Old

  • HIV Treatment Studies
    • A5359 Long-acting ART
  • Anchor Study (HPV)
  • Immune Modulators
    • Pennvax Study
  • Hepatitis Co-infection Studies
    • A5360 MINMON
  • Studies for Women
  • Lymphoma Studies
  • Kaposi's Sarcoma Studies
  • Non-AIDS Defining Cancer
  • HIV Prevention
    • PrEP for HIV Prevention
    • Team PrEP
  • HIV Treatment Studies
  • Anchor Study (HPV)
  • Immune Modulators
  • Hepatitis Co-infection Studies
  • Studies for Women
  • Lymphoma Studies
  • Kaposi's Sarcoma Studies
  • Non-AIDS Defining Cancer
  • HIV Prevention
  • A5359 Long-acting ART
  1. Home
  2. HIV Treatment Studies
  3. A5359 Long-acting ART

A5359 Long-acting ART

Long-Acting, Injectable ART

Viral suppression remains the main objective of ART (antiretroviral therapy) for HIV-infected individuals. However, achieving an undetectable viral load continues to be a challenge for many individuals. Among the obstacles that hinder ART success, poor drug adherence is responsible for most episodes of failure to achieve and maintain virologic suppression. Up to 25% of individuals on chronic ART may experience episodes episodes of non-adherence and only 51% of HIV-infected adults in the US are virally suppressed (1). This is a suboptimal outcome from both an individual and public health perspective. Thus, improving ART adherence remains of critical importance in HIV treatment.

Researchers are currently investigating long-acting & injectable forms of antiretroviral medications (LA-ART) as a potential alternative for people who struggle with adherence to present, oral treatments. In the LATTE-2 trial, researchers provided long-acting forms cabotegravir + rilpivirine to HIV-positive people who had not previously taken HIV treatment before in the United States and Spain. Injections occurred every four or eight weeks, depending on which study arm a person was randomized to. (2) At 160 weeks, 104 of 115 participants (90%) and 95 of 115 participants (83%) receiving the injectable regimen, every 8 and 4 weeks respectively, remained virally suppressed. Of the patients on the oral comparator arm who chose to switch to the injectable regimen at week 96, 33 of 34 participants (97%) and 10 of 10 participants (100%) remained virally suppressed on every 8 and 4-week dosing, respectively. (3) While researchers were excited by the results of the LATTE-2 study, the study did not specifically investigate the efficacy of LA-ART in people who struggle with adherence. Researchers hope to explore this question in this particular study. 


What is A5359?

This study is investigating if Long-Acting Injectable ART will be more successful for people who are non-adherent to their HIV medications than oral standard of care regimens. The main
advantages of LA ART in this population include infrequent dosing and directly observed therapy. A challenge for participants is that, to be eligible to receive LA ART, they will need to attain virologic suppression through adherence to their SOC oral medications. Financial incentives will be used during the first 20 weeks of the study to motivate participants to be adherent to an oral regimen until they are eligible to be randomized to either the LA ART arm or the standard of care arm.

Click here to learn more on the ACTG website. 

Requirements to Enter Study (things that must be true for you):

  • 18 years of age or older
  • Prescribed ART for at least 6 months
  • Screening HIV RNA greater than 200 copies
  • Evidence of non-adherence to HIV-medication, as defined as having one of the two: 
    • Poor virologic response within the last 18 months (HIV-1 RNA >200 copies/mL at two time points at least 4 weeks apart) 
    • Lost to clinical follow-up within the last 18 months (either no contact with provider or msised 2 appointments)
  • Women must not be pregnant, planning to become pregnant, or breastfeeding. Women who can become pregnant must agree to use 1 form of effective birth control. 

Exclusion Criteria (things that cannot be true about you):

  • Previous use of rilpivirine or cabotegravir 
  • Uncontrolled seizures 
  • Advanced liver disease 
  • Active Hep B infection
  • Chronic Hep C with planned or anticipate dose of anti-HCV therapy prior to Step 2

For more information about the UCLA CARE Center's clinical trials and research studies, please contact: 
(310) 557-9062 
CAREOutreach@mednet.ucla.edu

Facebook Twitter Instagram Youtube LinkedIn
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-800-UCLA-MD1
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap

Sign in to myUCLAhealth